Skip to content
Research Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · PerformanceResearch Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · PerformanceResearch Use OnlyThird-Party Tested in the USABatch-Verified COAsShips from the United StatesPrecision · Purity · Performance

Research use only·All materials are supplied to qualified research purchasers for in-vitro laboratory use. Not for human or veterinary use. Research Use Agreement

Compound Research

Retatrutide receptor targets: GIPR, GLP-1R and GCGR

GIPR, GLP-1R and GCGR are class B1 GPCRs with different tissue distributions and a shared Gs/cAMP output. Retatrutide is characterised by its distribution of activity across all three.

Last scientific review
September 2026
Published by
Pure Helix

The three receptors

ReceptorGeneProminent expression reportedPrimary in-vitro readout
GIP receptorGIPRPancreatic islet, adipose, central nervous systemcAMP accumulation
GLP-1 receptorGLP1RPancreatic islet, central nervous system, gastrointestinal tractcAMP accumulation, β-arrestin recruitment
Glucagon receptorGCGRHepatocytes, kidney, adiposecAMP accumulation

All three are class B1 (secretin-family) G-protein-coupled receptors coupling principally to Gs.

Why the glucagon receptor is the distinguishing target

Selective GLP-1 receptor agonists engage one of these receptors and dual incretin agonists engage two. The tri-agonist class is defined by the addition of glucagon receptor agonism, and GCGR expression is concentrated in a different tissue — the liver — than the islet-weighted GIPR and GLP-1R populations. Comparative work between agonist classes is therefore as much about which tissue model is used as about potency.

Profiling activity, receptor by receptor

  • Use monoreceptor cell lines. A system expressing more than one of the three cannot attribute a cAMP response to a single receptor.
  • Include the native agonist for each receptor — GIP, GLP-1(7-36)amide and glucagon respectively — as the in-run reference, and report potency relative to it.
  • Report the readout, cell background, incubation time and reference agonist with every potency value; cross-study EC50 comparison between different systems is unreliable.
  • Where signalling bias is the question, pair cAMP accumulation with a β-arrestin recruitment assay at the same receptor. Bias is a relationship between two readouts, not a property of one.
  • Confirm the identity and content of the lot in use before interpreting a potency shift — an under-filled or partially degraded vial reads as reduced potency at every receptor at once.

Reading the published potency data

The characterisation literature reports that LY3437943 is not equipotent across the three receptors; the balance between them is the engineered property under study. When citing a potency figure, cite the receptor, the assay and the reference agonist together with the number — a bare EC50 for a tri-agonist is not interpretable.

Research use

Pure Helix supplies materials for laboratory research use only. Nothing on this page is medical advice, and none of the material described is for human or veterinary use.

Primary literature and standards

  1. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022.
  2. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020.Methodological reference for cAMP versus β-arrestin profiling in this receptor family.
  3. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023.

Reference materials and documentation

Related reading